A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Jitkova, Yulia ^a   Gronda, Marcela ^a   Hurren, Rose ^a   Wang, Xiaoming ^a   Goard, Carolyn A ^a   Jhas, Bozhena ^a   Schimmer, Aaron D ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; EXCIPIENT; PYRUVIC ACID; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SCREENING; DRUG STABILITY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PH MEASUREMENT; ROOM TEMPERATURE; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOBLOTTING; LEUKEMIA, MYELOID, ACUTE; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTI-BACTERIAL AGENTS; ASCORBIC ACID; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HUMANS; IMMUNOBLOTTING; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, SCID; MINOCYCLINE; PYRUVIC ACID;

EID: 84901609121     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095281     Document Type: Article

References (25)

1. Wenzel R, Bate G, Kirkpatrick P (2005) Tigecycline. Nat Rev Drug Discov 4: 809-810.
2. Sum PE, Petersen P (1999) Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett 9: 1459-1462.
3. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT (1999) In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 43: 738-744. (Pubitemid 29165733)
4. Wyeth Pharmaceuticals Inc. 2012) Tygacil: Full Prescribing Information. Available online: http://labeling.pfizer.com/showlabeling.aspx?id=491 (Accessed 8 July 2013).
5. Giamarellou H, Poulakou G (2011) Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opin Drug Metab Toxicol 7: 1459-1470.
6. Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, et al. (2011) Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20: 674-688.
7. Bauer G, Berens C, Projan SJ, Hillen W (2004) Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2 + cleavage of 16S rRNA. J Antimicrob Chemother 53: 592-599. (Pubitemid 38499772)
8. Olson MW, Ruzin A, Feyfant E, Rush TS, 3rd, O'Connell J, et al. (2006) Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother 50: 2156-2166. (Pubitemid 43807538)
9. Jenner L, Starosta AL, Terry DS, Mikolajka A, Filonava L, et al. (2013) Structural basis for potent inhibitory activity of the antibiotic tigecycline during protein synthesis. Proc Natl Acad Sci U S A 110: 3812-3816.
10. Kehrein K, Bonnefoy N, Ott M (2013) Mitochondrial Protein Synthesis: Efficiency and Accuracy. Antioxid Redox Signal.
11. Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, et al. (2013) BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12: 329-341.
12. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, et al. (2010) Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 120: 142-156.
13. Schimmer AD, Skrtic M (2012) Therapeutic potential of mitochondrial translation inhibition for treatment of acute myeloid leukemia. Expert Rev Hematol 5: 117-119.
14. Fawzi MB, Zhu T, Shah SM, inventors; Wyeth LLC, assignee (2011 February 1) Tigecycline compositions and methods of preparation. United States patent US. 7,879,828
15. Bradford PA, Petersen PJ, Young M, Jones CH, Tischler M, et al. (2005) Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother 49: 3903-3909. (Pubitemid 41233048)
16. Hope R, Warner M, Mushtaq S, Ward ME, Parsons T, et al. (2005) Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines. J Antimicrob Chemother 56: 1042-1046. (Pubitemid 43009817)
17. Li C, Sutherland CA, Nightingale CH, Nicolau DP (2004) Quantitation of tigecycline, a novel glycylcycline [corrected] by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 811: 225-229. (Pubitemid 39446769)
18. Wiegand I, Hilpert K, Hancock RE (2008) Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3: 163-175. (Pubitemid 351266501)
19. Wang C, Curtis JE, Minden MD, McCulloch EA (1989) Expression of a retinoic acid receptor gene in myeloid leukemia cells. Leukemia 3: 264-269. (Pubitemid 19092758)
20. Warner JK, Wang JC, Takenaka K, Doulatov S, McKenzie JL, et al. (2005) Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia 19: 1794-1805. (Pubitemid 41486158)
21. Schimmer AD, Thomas MP, Hurren R, Gronda M, Pellecchia M, et al. (2006) Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. Cancer Res 66: 2367-2375.
22. Frezza C, Cipolat S, Scorrano L (2007) Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts. Nature Protocols 2: 287.
23. Pohanka M, Pejchal J, Snopkova S, Havlickova K, Karasova JZ, et al. (2012) Ascorbic acid: an old player with a broad impact on body physiology including oxidative stress suppression and immunomodulation: a review. Mini Rev Med Chem 12: 35-43.
24. Chauhan B, Arora VK, Srivastava J, inventors; Ranbaxy Laboratories Ltd., assignee (2009 November 5) Stable parenteral formulations of tigecycline. United States patent application US. 12/434,499. Publication number US 2009/02756660 A1
25. Petersen PJ, Bradford PA (2005) Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob Agents Chemother 49: 3910-3918. (Pubitemid 41233049)